The complaint targets a period between January 13, 2025, and January 29, 2026, alleging that the company misled shareholders about the efficacy of its Revita treatment. According to the filing, internal operational issues at clinical sites for the REMAIN-1 Midpoint Cohort compromised the integrity of efficacy results, a reality the firm failed to disclose to the public. These omissions allegedly led to an overstatement of the company’s commercial and regulatory prospects, distorting the perceived value of the business for potential investors.

Legal counsel for the plaintiffs, Howard G. Smith, is currently vetting investors who held GUTS stock during the specified timeframe to serve as lead representatives. While participation in the class action does not require immediate action for those who wish to remain absent members, those seeking to influence the litigation or discuss specific legal rights are encouraged to reach out to the Bensalem-based law firm directly. The firm can be contacted at 215-638-4847 or via their website to review individual claims.